Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease, of which an advanced form is non-alcoholic steatohepatitis (NASH). But how does this condition develop, and why is it associated with poor outcomes? In this podcast episode, Professor Zobair Younossi discusses the latest evidence on the pathogenesis and pathophysiology of NASH, and how it can lead to poor outcomes.
By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at hepatology.knowledgeintopractice.com, where you can see all episodes of the podcast as well as other free CME resources.
References:
Disclosures:
Professor Zobair Younossi declares the following:
Consultant: Merck, Gilead, Siemens, Intercept, Bristol Myers Squibb
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
Funding:
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.